Project Grant R01AG091320
Award Date 9/4/26
Completion Date 6/30/31
Dollars Obligated $616K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Phoenix, AZ 85004, USA
Similar Awards
- The National Institute on Aging awarded the University of Arizona $396,241 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal, multi-modal study tracking neuroplasticity changes in preclinical and prodromal Alzheimer's disease stages using transcranial magnetic stimulation (TMS) integrated with blood and MRI biomarkers. The study employs TMS to assess non-invasive, repeatable neurophysiological measures of neuroplasticity and correlates these...
- The National Institute on Aging awarded Temple University $132,448 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate NMDAR/TRPM4 signaling and mitochondrial dysfunction in Alzheimer's disease. The project tests the functional coupling of N-methyl-D-aspartate receptors (NMDARs) and TRPM4 channels as a central mechanism of neurotoxicity in Alzheimer's disease and related dementias. Research employs induced pluripotent stem cell organoids carrying AD-causing...
- The National Institute on Aging awarded New York University $642,063 under the Aging Research program (CFDA 93.866) on January 15, 2026, to investigate gabaergic circuit targets for modulating entorhinal cortex and hippocampal dynamics in Alzheimer's disease. The research examines vasoactive intestinal peptide and cholecystokinin inhibitory neuron microcircuits within hippocampal area CA1, with the hypothesis that modulating activity in these circuits can improve lateral entorhinal cortex–CA1...
- The National Institute on Aging awarded the University of Arizona $611,338 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop selective DYRK1A inhibitors for Alzheimer's disease treatment. The research targets dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a therapeutic intervention modulating tau, amyloid, and neuroinflammatory pathways in Alzheimer's disease. Prior work demonstrated that the DYRK1A inhibitor DYR533 improves behavioral and...
- The National Institute on Aging awarded the University of Pittsburgh $664,619 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop multiscale computational and experimental models of neurometabolic coupling across age-related cognitive decline and late-onset Alzheimer's disease. The research integrates in vivo two-photon microscopy, multispectral wide-field imaging, and magnetic resonance imaging to characterize the relationship between neuronal activity and metabolic...
- The National Institute on Aging awarded Georgetown University $156,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mitigation strategies for network dysfunction in Alzheimer's disease pathology. The project tests whether mild hyperpolarization can stabilize hippocampal network activity despite amyloid-beta-related impairment of excitatory amino acid transporters. The research quantifies sharp wave-ripples in ex vivo hippocampal slices from 5XFAD transgenic...
- The National Institute on Aging awarded Arizona State University $431,750 under the Aging Research program (CFDA 93.866) on September 1, 2026, to define the mechanisms underlying the protective effects of the RELN-COLBOS variant in Alzheimer's disease. The funded research leverages stem cell bioengineering, genome editing, and neurodegenerative disease modeling to elucidate the neuroprotective mechanisms of the RELN-COLBOS variant, a rare Reelin variant identified in a PSEN1 mutation carrier...
- The National Institute on Aging awarded the University of Southern California $695,789 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop HGEA-NET, a multiscale computational model of the hippocampus that integrates cell type-specific gene expression and connectivity data to understand how progressive neurodegeneration of vulnerable neuronal populations leads to hippocampal network dysfunction and cognitive decline in Alzheimer's disease. The project builds on USC's...
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $704,145 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and apply computational methods for inferring the natural history of Alzheimer's disease from sparse longitudinal molecular and neuroimaging data. The recipient will develop an innovative approach that leverages temporal signal in sparse longitudinal datasets to reconstruct the timeline of Alzheimer's disease progression and...